Tirzepatide (Mounjaro) Gets FDA Approval for Type 2 Diabetes Tirzepatide (Mounjaro) Gets FDA Approval for Type 2 Diabetes

Endocrinologists voice enthusiasm for the first approved agent for patients with type 2 diabetes that is a dual incretin agonist, but they also express concern about cost and patient accessibility.FDA Approvals
Source: Medscape Diabetes Headlines - Category: Endocrinology Tags: Diabetes & Endocrinology News Alert Source Type: news